CO5160287A1 - Formulacion de liberacion controlada de divalproex sodico - Google Patents
Formulacion de liberacion controlada de divalproex sodicoInfo
- Publication number
- CO5160287A1 CO5160287A1 CO99078240A CO99078240A CO5160287A1 CO 5160287 A1 CO5160287 A1 CO 5160287A1 CO 99078240 A CO99078240 A CO 99078240A CO 99078240 A CO99078240 A CO 99078240A CO 5160287 A1 CO5160287 A1 CO 5160287A1
- Authority
- CO
- Colombia
- Prior art keywords
- weight
- percent
- divalproex
- sodico
- formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Una forma de dosificación en tabletas de liberación controlada que comprendea) desde 50 porciento en peso hasta 55 porciento en peso de ingrediente activo seleccionado de un grupo conformado por ácido valproico, una sal ó éster farmacéuticamente aceptables del ácido valproico, divalproex sódico, y valpromida;b) desde 20 porciento en peso hasta 40 porciento en peso de hidroxipropilmetilcelulosa;c) desde 5 porciento en peso hasta 15 porciento en peso de lactosa, desde 4 porciento en peso hasta 6 porciento en peso de celulosa microcristalina, y desde 1 hasta 5 porciento en peso de dióxido de silicio que tiene un tamaño de partícula promedio que oscila entre 1 micrón y 10 micrones;todos los porcentajes en peso con base en el peso total de la forma de dosificación en tabletas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/216,650 US6419953B1 (en) | 1998-12-18 | 1998-12-18 | Controlled release formulation of divalproex sodium |
US12155799P | 1999-02-25 | 1999-02-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5160287A1 true CO5160287A1 (es) | 2002-05-30 |
Family
ID=26819594
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO99078240A CO5160287A1 (es) | 1998-12-18 | 1999-12-15 | Formulacion de liberacion controlada de divalproex sodico |
Country Status (25)
Country | Link |
---|---|
EP (1) | EP1140034B1 (es) |
JP (1) | JP2003513882A (es) |
KR (1) | KR20010101295A (es) |
CN (1) | CN1335769A (es) |
AR (1) | AR021443A1 (es) |
AT (1) | ATE254907T1 (es) |
AU (1) | AU2478900A (es) |
BG (1) | BG105665A (es) |
BR (1) | BR9916361A (es) |
CA (1) | CA2330480C (es) |
CO (1) | CO5160287A1 (es) |
CZ (1) | CZ20012201A3 (es) |
DE (1) | DE69913197T2 (es) |
DK (1) | DK1140034T3 (es) |
ES (1) | ES2212667T3 (es) |
HK (1) | HK1043043B (es) |
HU (1) | HUP0105463A3 (es) |
IL (1) | IL143407A0 (es) |
NO (1) | NO20012986L (es) |
PL (1) | PL356899A1 (es) |
PT (1) | PT1140034E (es) |
SI (1) | SI20624A (es) |
SK (1) | SK8252001A3 (es) |
TW (1) | TW585788B (es) |
WO (1) | WO2000037055A1 (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6713086B2 (en) | 1998-12-18 | 2004-03-30 | Abbott Laboratories | Controlled release formulation of divalproex sodium |
US20020025341A1 (en) * | 1998-12-18 | 2002-02-28 | Yihong Qiu | Controlled release formulation of divalproex sodium |
US6419953B1 (en) | 1998-12-18 | 2002-07-16 | Abbott Laboratories | Controlled release formulation of divalproex sodium |
US6511678B2 (en) | 1998-12-18 | 2003-01-28 | Abbott Laboratories | Controlled release formulation of divalproex sodium |
US6528090B2 (en) | 1998-12-18 | 2003-03-04 | Abbott Laboratories | Controlled release formulation of divalproex sodium |
WO2002051402A1 (en) * | 2000-12-22 | 2002-07-04 | Abbott Laboratories | Controlled release formulation of divalproex sodium |
US7297346B2 (en) | 2001-05-25 | 2007-11-20 | Cephalon Inc. | Pharmaceutical formulations of modafinil |
US7229644B2 (en) * | 2002-05-23 | 2007-06-12 | Cephalon, Inc. | Pharmaceutical formulations of modafinil |
US20040005357A1 (en) * | 2002-07-03 | 2004-01-08 | Sherman Bernard Charles | Extended-release tablets comprising divalproex sodium |
US20040048931A1 (en) | 2002-07-12 | 2004-03-11 | Craig Heacock | Modafinil pharmaceutical compositions |
US20040116532A1 (en) | 2002-09-13 | 2004-06-17 | Craig Heacock | Pharmaceutical formulations of modafinil |
JP2006520390A (ja) * | 2003-03-14 | 2006-09-07 | ムルイェ、ニルマル | 徐放性錠剤の製造方法 |
HUP0301537A3 (en) * | 2003-06-03 | 2005-07-28 | Egis Gyogyszergyar Nyilvanosan | Deramcyclane fumarate tablets and process for producing them |
US7713550B2 (en) | 2004-06-15 | 2010-05-11 | Andrx Corporation | Controlled release sodium valproate formulation |
WO2006025029A2 (en) * | 2004-08-31 | 2006-03-09 | Ranbaxy Laboratories Limited | Extended release composition of divalproex |
KR20070102563A (ko) * | 2005-01-26 | 2007-10-18 | 엘란 파마 인터내셔널 리미티드 | 정신병치료제를 함유하는 조절방출형 조성물 |
US20070202164A1 (en) * | 2006-02-28 | 2007-08-30 | Hutchison Medipharma Enterprises Limited | Andrographis Extract Formulations |
AU2010248292B2 (en) * | 2009-05-12 | 2014-06-12 | Amorepacific Corporation | Composition for preventing hair loss or for stimulating hair growth |
WO2012121862A2 (en) * | 2011-02-17 | 2012-09-13 | University Of Florida Research Foundation | Valproic acid derivative compounds |
CN102138911B (zh) * | 2011-03-28 | 2012-12-12 | 孙卫东 | 一种双丙戊酸钠缓释片及其制备方法 |
CN102895201B (zh) * | 2011-07-26 | 2014-09-10 | 北大方正集团有限公司 | 丙戊酸半钠片剂及其制备方法 |
HUE051406T2 (hu) | 2012-11-14 | 2021-03-01 | Grace W R & Co | Biológiailag aktív anyagot és rendezetlen szervetlen oxidot tartalmazó kompozíciók |
CN105012264B (zh) * | 2014-04-16 | 2019-11-29 | 四川科瑞德制药股份有限公司 | 丙戊酸钠缓释片及其制备工艺和用途 |
CN106389368B (zh) * | 2015-07-29 | 2021-11-12 | 四川科瑞德制药股份有限公司 | 一种丙戊酸钠缓释制剂及其制备工艺和用途 |
CN105456218A (zh) * | 2015-12-07 | 2016-04-06 | 黑龙江省智诚医药科技有限公司 | 一种丙戊酸镁缓释片及其制备方法 |
CN107028907B (zh) * | 2016-02-04 | 2021-05-14 | 成都康弘药业集团股份有限公司 | 一种双丙戊酸钠缓释片 |
CN114681419A (zh) * | 2020-12-28 | 2022-07-01 | 湖南省湘中制药有限公司 | 一种丙戊酰胺缓释片的组合物及其制备方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5169642A (en) * | 1988-06-24 | 1992-12-08 | Abbott Laboratories | Sustained-release drug dosage units |
US5009897A (en) * | 1988-06-24 | 1991-04-23 | Abbott Laboratories | Pharmaceutical granules and tablets made therefrom |
FR2643556B1 (fr) * | 1989-02-27 | 1993-03-05 | Sanofi Sa | Composition pharmaceutique a liberation prolongee d'acide valproique |
IL96311A (en) * | 1989-12-01 | 1995-05-26 | Abbott Lab | Medications with delayed release |
US5075114A (en) * | 1990-05-23 | 1991-12-24 | Mcneil-Ppc, Inc. | Taste masking and sustained release coatings for pharmaceuticals |
TW224049B (es) * | 1991-12-31 | 1994-05-21 | Sunkyong Ind Ltd | |
TW222585B (es) * | 1992-09-11 | 1994-04-21 | Hoechst Ag | |
JP3552285B2 (ja) * | 1993-08-03 | 2004-08-11 | 三菱化学株式会社 | 経口コレステロール低下剤 |
GB9501127D0 (en) * | 1995-01-20 | 1995-03-08 | Wellcome Found | Tablet |
CA2216215A1 (en) * | 1997-04-05 | 1998-10-05 | Isa Odidi | Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity |
-
1999
- 1999-12-09 PL PL99356899A patent/PL356899A1/xx not_active Application Discontinuation
- 1999-12-09 WO PCT/US1999/029204 patent/WO2000037055A1/en not_active Application Discontinuation
- 1999-12-09 IL IL14340799A patent/IL143407A0/xx unknown
- 1999-12-09 DE DE69913197T patent/DE69913197T2/de not_active Expired - Lifetime
- 1999-12-09 SI SI9920100A patent/SI20624A/sl not_active IP Right Cessation
- 1999-12-09 SK SK825-2001A patent/SK8252001A3/sk unknown
- 1999-12-09 ES ES99968104T patent/ES2212667T3/es not_active Expired - Lifetime
- 1999-12-09 CZ CZ20012201A patent/CZ20012201A3/cs unknown
- 1999-12-09 AU AU24789/00A patent/AU2478900A/en not_active Abandoned
- 1999-12-09 CA CA002330480A patent/CA2330480C/en not_active Expired - Fee Related
- 1999-12-09 PT PT99968104T patent/PT1140034E/pt unknown
- 1999-12-09 KR KR1020017007649A patent/KR20010101295A/ko not_active Application Discontinuation
- 1999-12-09 AT AT99968104T patent/ATE254907T1/de active
- 1999-12-09 EP EP99968104A patent/EP1140034B1/en not_active Expired - Lifetime
- 1999-12-09 BR BR9916361-6A patent/BR9916361A/pt not_active Application Discontinuation
- 1999-12-09 HU HU0105463A patent/HUP0105463A3/hu unknown
- 1999-12-09 DK DK99968104T patent/DK1140034T3/da active
- 1999-12-09 CN CN99814629A patent/CN1335769A/zh active Pending
- 1999-12-09 JP JP2000589166A patent/JP2003513882A/ja active Pending
- 1999-12-15 CO CO99078240A patent/CO5160287A1/es unknown
- 1999-12-17 AR ARP990106552A patent/AR021443A1/es not_active Application Discontinuation
- 1999-12-18 TW TW088122338A patent/TW585788B/zh not_active IP Right Cessation
-
2001
- 2001-06-15 NO NO20012986A patent/NO20012986L/no not_active Application Discontinuation
- 2001-07-03 BG BG105665A patent/BG105665A/bg unknown
-
2002
- 2002-03-28 HK HK02102407.1A patent/HK1043043B/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
IL143407A0 (en) | 2002-04-21 |
PT1140034E (pt) | 2004-03-31 |
PL356899A1 (en) | 2004-07-12 |
NO20012986D0 (no) | 2001-06-15 |
WO2000037055A1 (en) | 2000-06-29 |
SK8252001A3 (en) | 2001-12-03 |
EP1140034A1 (en) | 2001-10-10 |
ATE254907T1 (de) | 2003-12-15 |
DE69913197D1 (de) | 2004-01-08 |
NO20012986L (no) | 2001-08-15 |
CA2330480A1 (en) | 2000-06-29 |
EP1140034B1 (en) | 2003-11-26 |
JP2003513882A (ja) | 2003-04-15 |
HUP0105463A3 (en) | 2003-03-28 |
HUP0105463A2 (hu) | 2002-05-29 |
BR9916361A (pt) | 2002-11-05 |
TW585788B (en) | 2004-05-01 |
HK1043043B (zh) | 2004-09-10 |
SI20624A (sl) | 2002-02-28 |
ES2212667T3 (es) | 2004-07-16 |
CZ20012201A3 (cs) | 2001-09-12 |
BG105665A (bg) | 2002-03-29 |
KR20010101295A (ko) | 2001-11-14 |
DK1140034T3 (da) | 2004-03-08 |
AU2478900A (en) | 2000-07-12 |
HK1043043A1 (en) | 2002-09-06 |
CA2330480C (en) | 2002-05-21 |
AR021443A1 (es) | 2002-07-17 |
CN1335769A (zh) | 2002-02-13 |
DE69913197T2 (de) | 2004-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5160287A1 (es) | Formulacion de liberacion controlada de divalproex sodico | |
HUP0101237A1 (hu) | Elnyújtott kioldódású gyógyszerkészítmények | |
ATE333265T1 (de) | Oral anzuwendende schnell zerfallende feste darreichungsformen | |
IT1276689B1 (it) | Forma farmaceutica solida ad uso orale | |
BRPI0015567B8 (pt) | composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica | |
AR035195A1 (es) | Formulaciones de liberacion sostenida para secretagogos de hormona del crecimiento | |
AR084101A2 (es) | Comprimido de carga de droga alta y proceso para su preparacion | |
AR028299A1 (es) | Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes. | |
ES2162517T3 (es) | Composicion farmaceutica que comprende una combinacion de metformin y fibrato y su uso en la preparacion de medicamentos destinados a reducir la hiperglicemia. | |
ITMI931631A1 (it) | Composizioni farmaceutiche a rilascio controllato a base di uno o piu' sali farmaceuticamente accettabili dell'acido gamma-idrossi-butirrico. | |
ES2530719T3 (es) | Formulaciones de oxicodona para ser administradas una vez al día | |
EA200700049A1 (ru) | Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением | |
MY100721A (en) | Therapeutic agent. | |
AR018829A1 (es) | Formulaciones farmaceuticas solidas de rapida desintegracion, administrables via oral y procedimiento para prepararlos | |
AR017512A1 (es) | Tabletas de metilcelulosa rapidamente desintegrables para administracion por via oral y procedimiento para prepararlas | |
CL2009001682A1 (es) | Composición farmacéutica espontáneamente dispersable para administración oral que comprende n-benzoil-estaurosporina; método para incrementar los niveles de biodisponibilidad. (divisional de la solocitud 333-00). | |
PT1131050E (pt) | Formulacoes galenicas que se desintegram rapidamente na boca e metodo para as preparar | |
MY122124A (en) | Solid pharmaceutical composition containing benzofurane derivatives | |
CO5280073A1 (es) | Composiciones | |
DE69940557D1 (de) | Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung | |
PE20001414A1 (es) | Procedimiento de preparacion de globulos que contienen 50% en peso o mas de una sustancia farmaceutica de hidrosolubilidad | |
EA200001201A3 (ru) | Таблетка с основой, позволяющая осуществлять пролонгированное высвобождение триметазидина после введения оральным путем | |
ES2130081B1 (es) | Comprimido de maleato de trimebutina con recubrimiento laminar. | |
CO4940406A1 (es) | Composiciones de paracetamol de accion rapida | |
IT1270239B (it) | Composizione farmaceutica solida contenente acido (s)-2-(4- isobutilfenil) propionico come principio attivo |